 The FDA has granted Fast Track designation to Fulcrum Therapeutics Incs NASDAQ: FULC losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy FSHD. Fulcrum is on track to report full data from the ReDUX4 Phase 2b trial at the virtual FSHD International Research Congress to be held next month. 